References
- Muston D, Downs A, Rives V. An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat. 2009;20(5):266–275.
- Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol. 2005;85(5):424–428.
- Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P, A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: A prospective, randomized study. J Dermatolog Treat. 2003;14(2):99–106.
- Morton C, Campbell S, Gupta G, Keohane S, Lear J, Zaki I, Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: A multicentre, randomized controlled study. Br J Dermatol. 2006;155(5):1029–1036.
- Szeimies RM, Karrer S, Radakovic-Fijan S, Tanew A, Calzavara-Pinton PG, Zane C, Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. J Am Acad Dermatol. 2002;47(2):258–262.
- Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, Indirect comparisons of competing interventions. Health Technol Assess. 2005;9(26):1–134.
- National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008.
- Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol. 2007;157(1):133–141.
- Jorizzo J, Dinehart S, Matheson R, Moore JK, Ling M, Fox TL, Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007;57(2):265–268.
- Tschen EH, Wong DS, Pariser DM, Dunlap FE, Houlihan A, Ferdon MB. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: Phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol. 2006;155(6):1262–1269.
- Metvix 160 mg/g cream summary of product characteristics. Electronic Medicines Compendium ; 2007 [cited]. Accessed 2010 April 18. Available from: http://www.medicines.org.uk/EMC/medicine/11913/SPC/Metvix+160+mg+g+cream/
- Aldara 5% cream summary of product characteristics. Electronic Medicines Compendium ; 2007 [cited]. Accessed 2010 April 18. Available from: http://www.medicines.org.uk/EMC/medicine/8/SPC/Aldara+5%25+Cream/
- Littenberg B, Partilo S, Licata A, Kattan MW. Paper Standard Gamble: the reliability of a paper questionnaire to assess utility. Med Decis Making. 2003;23(6):480–488.
- Chen SC, Bayoumi AM, Soon SL, Aftergut K, Cruz P, Sexton SA, A catalog of dermatology utilities: A measure of the burden of skin diseases. J Investig Dermatol Symp Proc. 2004;9(2):160–168.
- Mooney G. QALYs: Are they enough? A health economist's perspective. J Med Ethics. 1989;15(3):148–152.
- Nord E, Enge AU, Gundersen V. QALYs: Is the value of treatment proportional to the size of the health gain? Health Econ. Epub 2009 May 20.
- Brouwer W, van Exel J, Baker R, Donaldson C. The new myth: The social value of the QALY. Pharmacoeconomics. 2008;26(1):1–4.
- Briggs AH, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.